¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-17
±³À°ÀÏÀÚ : 2023-06-17
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ / ÄÁÆÛ·±½º·ë 1~3

±³À°ÁÖÁ¦ : "2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ"

ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ
´ã´çÀÚ : ÃÖÀº¿µ
¿¬¶ôó : 070-8873-6030  

À̸ÞÀÏ : k-iscp@naver.com

±³À°Á¾·ù : ³»°ú, ½Å°æ¿Ü°ú

Âü¼®¿¹»óÀÎ : 160¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:00~09:20 Optimal medical treatment after ablation or electrical cardioversion of atrial fibrillation ÃÖÀ±¿µ (°í·ÁÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:20~09:40 Second-line medication for ischemic ventricular tachyarrhythmia ±èÈ­Áß(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú )

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:40~10:00 Medical treatment for inherited primary arrhythmia syndrome ±è¹Î (ÃæºÏÀÇ´ë ½ÉÀå³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 10:00~10:20 Decision making for the recurred AF after ablation Á¤Çü±â (¿ø±¤ÀÇ´ë ¼øȯ±â³»°ú)

Åä·Ð 06¿ù 17ÀÏ AIȦ 10:20~10:30 Åä·Ð ()

ÈÞ½Ä 06¿ù 17ÀÏ 10:30~10:50 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 10:50~11:10 Aspirin vs. Clopidogrel for chronic maintenance monotherapy after PCI: HOST-EXAM extended study ¹Ú°æ¿ì(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:10~11:30 CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk Á¶»óÈ£(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:30~11:50 PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction ÃÖÀÍÁØ(°¡Å縯ÀÇ´ë ½ÉÀåÇ÷°ü³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:50~12:10 LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients With Coronary Artery Disease ¼Û¿µºó(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)

Åä·Ð 06¿ù 17ÀÏ AIȦ 12:10~12:20 Åä·Ð ()

±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 10:50~11:10 How to control hypertriglyceridemia and low HDL? ¿À±Ôö(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:10~11:30 Statin + Ezetimibe vs high dose statin ±è»óÇö(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:30~11:50 Co-enzyme Q10 and statin ÀÌÇØ¿µ(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:50~12:10 ¼øȯ±â ¿Ü·¡È¯ÀÚ¿¡¼­ ÀÚ°¡Åõ¿©ÁÖ»ç ÇöȲ ¹× ±³À° ¹éÁö¿ø(ºÐ´ç¼­¿ï´ëº´¿ø ¾àÁ¦ºÎ)

Åä·Ð 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 12:10~12:20 Åä·Ð ()

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 12:20~12:40 GLP1 agonist in obesity and diabetes control ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú)

½Ä»ç 06¿ù 17ÀÏ 12:40~13:30 ½Ä»ç ()

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 13:30~13:50 What ±èÇзÉ(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 13:50~14:10 New pipelines for hypertension ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 14:10~14:30 Comparison of calcium channel blockers ÀÌÀº¹Ì(¿ø±¤ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 14:30~14:50 Comparison of thiazide diuretics ±è´ëÈñ(¿ï»êÀÇ´ë ½ÉÀå³»°ú)

Åä·Ð 06¿ù 17ÀÏ AIȦ 14:50~15:00 Åä·Ð ()

ÈÞ½Ä 06¿ù 17ÀÏ 15:00~15:20 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 15:20~15:40 Myocardial function recovery at HFrEF ¹Ú¹ÎÁ¤(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú )

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 15:40~16:00 Severe hypercholesterolemia in very thin young woman ¹ÚÀçÀÏ(¼­¿ï´ëÇб³º´¿ø ³»°ú )

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:00~16:20 Pharmacological treatment of AF À̼öÇö(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:20~16:40 Optimal treatment of resistant hypertension : Difficult  control ±èÇöÁø(ÇѾçÀÇ´ë ½ÉÀå³»°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:40~16:50 Defer Revascularization of Vulnerable Plaque in NSTEMI ±èÈ£¿¬ (¿ï»êÀÇ´ë ½ÉÀå³»°ú)

Åä·Ð 06¿ù 17ÀÏ AIȦ 16:50~17:00 Åä·Ð ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-17
´ÙÀ½±Û ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) ´Ù¾çÇÑ ±¸°­Áúȯ¿¡ ´ëÇÑ Á¢±Ù : 2023-06-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 37 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 35 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 31 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 27 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 32 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 49 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 27 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 24 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 24 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 24 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 21 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 23 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 28 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 28 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷